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Angiotensin-converting enzyme 2 (ACE2) is a monocarboxypeptidase of the renin-angiotensin-system (RAS) which is known
to cleave several substrates among vasoactive peptides. Its preferred substrate is Angiotensin II, which is tightly involved in the
regulation of important physiological functions including ﬂuid homeostasis and blood pressure. Ang 1–7, the main enzymatic
product ofACE2,became increasinglyimportantin the literature in recent years, asitwas reported to counteract hypertensive and
ﬁbrotic actions of Angiotensin II via the MAS receptor. The functional connection of ACE2, Ang 1–7, and the MAS receptor is
also referred to as the alternative axis of the RAS. In the present paper, we describe the recombinant expression and puriﬁcation of
human and murine ACE2 (rhACE2 and rmACE2). Furthermore, we determined the conversion rates of rhACE2 and rmACE2 for
diﬀerentnaturalpeptide substratesinplasmasamplesanddiscoveredspecies-speciﬁc diﬀerences insubstratespeciﬁcities,probably
leading to functional diﬀerences in the alternative axis of the RAS. In particular, conversion rates of Ang 1–10 to Ang 1–9 were
found to be substantially diﬀerent when applying rhACE2 or rmACE2 in vitro. In contrast to rhACE2, rm ACE2 is substantially
less potent in transformationof Ang 1–10 to Ang 1–9.
1.Introduction
The classical renin-angiotensin-system (RAS)is a proteolytic
cascade which is constituted by multiple enzymes and eﬀec-
tor peptides. The cascade starts when Angiotensin I (Ang
1–10) is released from the propeptide angiotensinogen by
kidney-secreted renin. The peptide metabolites produced
from Ang 1–10 by a variety of proteases act as ligands for
angiotensin receptors in diﬀerent tissues leading to a diversi-
ﬁedpanelofphysiologicalfunctionsmediatedbyangiotensin
peptides [1].
Angiotensin II (Ang 1–8) is one of the most extensively
studied angiotensin peptides. It is mainly produced by
the proteolytic action of angiotensin-converting enzyme
(ACE) by removal of the two C-terminal amino acids from
Ang 1–10.Ang 1–8isabletobindtoseveralcellularreceptors
leading to a variety of physiologic eﬀects among diﬀerent
tissues and cell types [2]. Importantly, increased levels of
Ang 1–8 are reported to be associated with life-threatening
pathologic conditions including hypertension, congestive
heartfailure,chronickidneydisease,andalsotumorprogres-
sion [3]. Ang 1–8 was described to directly increase blood
pressure and vessel permeability, to induce Na reabsorption
and ROS production and excert proinﬂammatory and pro-
liferative eﬀects on various cell types [4, 5].
Thedisease-promoting functions ofAng1–8convertitto
a favorable therapeutic target in the treatment of many dis-
e a s e sm a i n l yb yp r e v e n t i n gi t sf o r m a t i o nb yl o w - m o l e c u l a r -
weight compounds inhibiting appropriate enzymes of the
RAS cascade. An alternative way of decreasing Ang 1–8 levels2 International Journal of Hypertension
became available over the recent years and uses recombinant
angiotensin-converting enzyme 2 (ACE2) to lower Ang 1–
8l e v e l s .A C E 2i n a c t i v a t e sA n g1 – 8b yc l i p p i n go ﬀ one C-
terminal phenylalanine [6], while Ang 1–7 is generated. Ang
1–7 is known to take over Ang 1–8 antagonistic functions by
activatingtheMASreceptor[7–9]andthereforeisthoughtto
be the key eﬀector peptide of the so-called alternative RAS.
Therefore, the monocarboxypeptidase ACE2 is a key
activator of the alternative RAS and is critically involved in
the regulation of the classical RAS, which is known to be
functionallyimportantinthevascularsystemandinavariety
of organs [6, 10, 11]. The biological function of the RAS
has been investigated in cardiovascular [12, 13], pulmonary
[14], ﬁbrotic [15], nephrologic [13], and artheriosclerotic
[16]m o d e l s .
Throughout all these studies the loss of ACE2 activity in
knock-out variants induced pathologies which could be
restored by systemic administration of the recombinant
enzyme. ACE2 therefore can be regarded as one of the key
players ofthe renin-angiotensin-system (RAS)being respon-
sible for ﬂuid homeostasis, blood pressure regulation, in-
ﬂammatory processes,andcellproliferation.ACE2isamem-
brane anchored glycoprotein which is expressed in most
organs and blood vessels and recognizes multiple peptide
substrates within the RAS and other peptide hormone sys-
tems. Among its substrates beside Ang 1–8, Ang 1–10,
and des-Arg-bradykinin, Apelins and Dynorphins have been
reported to be cleaved by ACE2 in vitro [17]w i t hA n g1 – 8
being the preferred substrate regarding conversion rates [18].
We recombinantly expressed both human ACE2
(rhACE2) and murine ACE2 (rmACE2) and compared their
substrateconversionratesin vitro andinbloodplasma which
represents the natural compartment of enzyme action. In
previously mentioned murine knock-out models, rhACE2
was frequently used to restore ACE2 activity. Despite the fact
that sequence coverage between murine and human ACE2
is only 83% [19], it has been assumed that the enzyme has
the same catalytic activity and function. In this work we
will highlight species-speciﬁc diﬀerences between human
and murine ACE2 regarding their function of keeping the
balance between the classical and the alternative RAS.
2.MaterialandMethods
2.1. Recombinant Expression of Murine and Human ACE2.
The extracellular domains of human or murine ACE2 [6]
were recombinantly expressed in CHO cells under serum-
free conditions. The sequence identity between rhACE2 and
rmACE2 accounts to 84% which leads to minor alterations
in physicochemical properties and altered patterns in post-
translational modiﬁcations, especially N-glycosylation. Both
expression products were puriﬁed by sequentially perform-
ing a capture step on a DEAE-Sepharose, ammonium sulfate
precipitation, followed by a puriﬁcation step on a HIC-
Phenyl Sepharose column and a ﬁnal polishing step on a
Superdex 200 gel ﬁltration column. The purity of rhACE2
and rmACE2 was determined by high-performance liquid
chromatography (HPLC) and was found to exceed 98%. The
concentrations of ﬁnal ACE2 preparations were determined
by size-exclusion chromatography (SEC) and in line with
photometric measurement at 280nm and peak integration
(OD280:r h A C E 2 :ε = 1621 L∗mol−1∗cm−1,r m A C E 2 :ε =
1750 L∗mol−1∗cm−1).
2.2. Native PAGE. 2μg ofrmACE2 and rhACE2 were applied
on a precast native 3–12% gradient gel (Invitrogen). Anode
buﬀer (50mM Bis/Tris, 50mM Tricine) and cathode buﬀer
(Invitrogen NativePAGE Cathode Buﬀer Additive, 50mM
Bis/Tris, 50mM Tricine) were used to run the gel. 40% glyc-
erol, 200mM Bis/Tris, and 200mM Tricine were used as
a loading buﬀer. NativeMark Unstained Protein Standard
(Thermo Scientiﬁc) was used for estimation of molecular
weights in Coomassie Blue-stained gels. The gel was run at
150V for 80min. Proteins were stained in gel using NOVEX
Colloidal Blue Staining Kit according to manufacturers’
recommendations.
2.3. SDS-PAGE. Samples were analyzed by SDS-PAGE using
a 4–12% precast gradient gel (NuPage) following reductive
denaturation for 5min at 95◦C. BenchMark Protein Ladder
was run on the same gel to allow molecular weight estima-
tions. The gel was run in NuPage MES SDS Running Buﬀer
(Invitrogen) at 150V for 80min. In gel protein staining
was performed using a NOVEX Colloidal Blue Staining Kit
according to manufacturer’s protocol.
2.4. Kinetic Assays for rmACE2 and rhACE2. Substrate spe-
ciﬁc turnover rates for rhACE2 and rmACE2 were deter-
mined by in vitro kinetic analysis of Ang 1–8 and Ang 1–10
cleavagefollowed by HPLC-based quantiﬁcation of substrate
and product concentrations. Enzyme reactions were started
by adding a deﬁned amount of enzyme to substrate dilutions
in MES-buﬀer (50mM MES, 300mM NaCl, 10μMZ n C l 2,
0.01% Brij-35, pH 6.5) which were previously equilibrated
at 37◦C. Aliquots of the reaction mixes were taken every 10
minutes and stopped by addition of 0.5M EDTA to a ﬁnal
concentration of 100mM before HPLC-based quantiﬁcation
of peptides.
2.5. HPLC-Based Quantiﬁcation of Angiotensin Peptides. The
concentration of peptides in enzymatic reactions was quan-
tiﬁed by detection of peaks eluted from the HPLC column
using an in-line diode array detector. Chromatography was
performed by running a gradient on a reversed-phase matrix
(Source 5RPC, 4.6×150mm, 5μm) with 0.08% H3PO4 in
water as mobile phase A and 40% acetonitrile in water and
0.08% H3PO4 as mobile phase B. The optical density at
280nM was recorded inline forall eluting peaks, and peptide
concentrationswerecalculatedviacalibrationcurvesforeach
individual peptide.
2.6. Ex Vivo Incubation of Plasma Samples. Anticoagulated
blood was collected from healthy volunteers, and plasma was
separated by 10 minutes centrifugation at 3000 RCF. Fol-
lowing addition of 100pg/mL recombinant human renin
(Sigma) to isolated blood plasma, rmACE2 or rhACE2 was
addedtothesamples.After10minutesofincubationat37◦C,International Journal of Hypertension 3
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Figure 1: Batch quality of recombinant human and murine ACE2. (a) Equal amounts (5μg) rmACE2 and rhACE2 were analyzed by size-
exclusion chromatography. The elution was continuously monitored by in-line measurement of the absorbance at 280nm. The eluted peaks
for puriﬁed rmACE2 (blue) and rhACE2 (red) are shown in the chromatogram and given in absorption units (mAU). (b) Equal amounts
(7μg) of rmACE2 (m) and rhACE2 (h) were subjected to SDS-PAGE analysis followed by in-gel protein staining with Coomassie Brilliant
Blue.Selected markerbandsaredepicted inthegraphto allowtheestimationofmolecularweights.(c)Equal amounts(2μg)ofrmACE2(m)
and rhACE2 (h) were analyzed in native PAGE followed by in-gel protein staining with CoomassieBrillant Blue as described in Section 2.
in the presence or absence of Lisinopril (Sigma), samples
were chilled on ice and immediately subjected to LC-MS/MS
analysis.
2.7. RAS-Fingerprinting: LC-MS/MS Quantiﬁcation of Angi-
otensin Peptides. Plasma samples were spiked with 100pg/
mL stable-isotope-labeled internal standards and subjected
to solid-phase extraction using Sep-Pak cartridges (Waters)
according to manufacturers protocol. Following elution and
solvent evaporation, samples were reconstituted in 50μL
50% acetonitrile/0.1% formic acid and subjected to LC-
MS/MS analysis using a reversed-phase analytical column
(Luna C18, Phenomenex) using a gradient ranging from
10% acetonitrile/0.1% formic acid to 70% acetonitrile/0.1%
formic acid in 9 minutes. The eluate was analyzed in line
with a QTRAP-4000 mass spectrometer (AB Sciex) operated
in the MRM mode using dwell times of 25 msec at a cone
voltage of 4000 volts and a source temperature of 300◦C.
For each peptide and corresponding internal standards, two
diﬀerent mass transitions were measured. Angiotensin pep-
tide concentrations were calculated by relating endogenous
peptide signals to internal standard signals provided that
integrated signals achieved a signal-to-noise ratio above 10.
The quantiﬁcation limits for individual peptides were found
to range between 1pg/mL and 5pg/mL undiluted plasma.
3.Results
3.1. Quality Control of rmACE2 and rhACE2 Reveals a High
Degree of Purity and Functional Protein Structure. The qual-
ity of the frozen enzyme batches used for later functional
analysis was analyzed regarding enzyme purity and char-
acteristics. The investigation of rmACE2 and rhACE2 by
size-exclusion chromatography revealed that no detectable
contaminations were present in the enzyme preparations.
The protein concentration in the enzyme batches was deter-
mined by measuring the peak absorbance inline at 280nm,
peak integration, and subsequent calculation based on
the corresponding extinction coeﬃcients. Both ACE2 vari-
ants appeared as baseline separated sharp peaks. rhACE2
and rmACE2 were found to slightly diﬀer in retention
times, pointing to a diﬀerence in their hydrodynamic molec-
ular diameter which was found to be lower for rmACE2
(Figure 1(a)).Inordertofurther investigatethisobservation,
we employed SDS-PAGE analysis, revealing a mass diﬀerence
under denatured conditions (Figure 1(b)), indicating the
presence of additional covalent mass-increasing modiﬁca-
tions in rhACE2. The mass shift was found to be caused by
twoadditionalglycosylationsites inthehuman enzyme(data
not shown). According to our results, both recombinant
ACE2versionsapparentlyoccurasnoncovalenthomodimers
in physiological solution. These ﬁndings and their possible
implications will be discussed in detail elsewhere. The cal-
culated molecular weights of monomeric rmACE2 and
rhACE2 are 85.2kDa and 85.3kDa, respectively. RmACE2
and rhACE2 werebothfound togiveasingle bandatapprox-
imately 170kDa in native PAGE, giving evidence for a ho-
modimer occurrence of both recombinant ACE2 versions
(Figure 1(c)). These ﬁndings indicate that the recombinant
enzymes, produced and puriﬁed according to our protocol,
are free of contaminants and possess their natural folding
and tertiary structure.
3.2. Recombinant ACE2 of Mouse and Human Origin Possess
Diverging Turnover Rates for Natural Peptide Substrates In
Vitro. Based on the concentrations and purity of enzyme
batchespreviouslydetermined,weinvestigatedthebiological
activity of rhACE2 and rmACE2 in an in vitro system. There-
fore, we coincubated deﬁned amounts of puriﬁed enzymes
with an excess of Ang 1–8 and Ang 1–10, respectively, which4 International Journal of Hypertension
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Figure 2: In vitro turnover rates of rhACE2 and rmACE2. The turnover rates for natural ACE2 substrates were determined by in vitro
incubation with excess amounts of substrate followed by reversed-phase HPLC analysis. Therefore, 14nM rmACE2 or rhACE2 were
coincubated with 65μMA n g1 – 8( a )i nM E Sb u ﬀer and aliquots were taken at indicated time points. The resulting time courses are shown
in the graphs. The turnover rates for Ang 1–10 were determined in MES buﬀer containing1.5μM rmACE2 or rhACE2 and 65μM Ang 1–10
(b) as described in Section 2. Each time point was analyzed in true triplicates and standard deviations are given in the graphs together with
linear regressions of the measured values.
represent natural substrates for ACE2. We found that
rhACE2 as well as rmACE2 converted Ang 1–8 to Ang 1–7
at comparable rates (Figure 2(a)). The calculation of kcat via
the graphically determined product formation rate and
substratedegradationraterevealedthattheturnovernumber
of rhACE2 for Ang 1–8 was 1.2-fold higher than that for
rmACE2(Table 1).Asanalternativenaturalangiotensinsub-
strate for ACE2, we also employed Ang 1–10 cleavage in
vitro. Surprisingly, rhACE2 turned out to be much more
eﬀective in performing the cleavage of Ang 1–10 to Ang 1–
9c o m p a r e dt or m A C E 2( Figure 2(b)). The calculation of
Ang 1–10 related turnover rates for rhACE2, and rmACE2
revealed that the Ang 1–10 related kcat for rhACE2 was 15-
foldhigherthanthatforrmACE2(1.8×10−2 versus1.2×10−3
s−1). Furthermore, the comparison of turnover numbers for
diﬀerent substrates revealed that Ang 1–8 is the preferred
substrate for both enzymes in vitro with a 42-fold higher
turnover number for rhACE2 (0.77s−1) and a 492-fold
higher turnover number for rmACE2 (0.62s−1)c o m p a r e dt o
Ang 1–10 (Table 1). These results demonstrate that human
and murine ACE2 possess substantially diﬀerent turnover
numbers for Ang 1–10, pointing to a species-speciﬁc func-
tional diversity of the enzyme.
3.3. Species-Speciﬁc Substrate Speciﬁcity of ACE2 AﬀectsEndo-
genous Plasma Angiotensin Levels Ex Vivo. In order to inves-
tigate the substrate speciﬁcity ofrhACE2 and rmACE2 under
physiologic conditions, we assessed the impact of the two
enzymes on the human RAS in blood plasma. Therefore, we
simulated a pathological hyperactivated RAS by addition of
recombinant human renin to anticoagulated human blood
plasma. Going in line with our previous in vitro ﬁndings, the
addition of rhACE2 or rmACE2 to ex vivo incubated plasma
samples revealedthat both enzymes eﬀectivelydegraded Ang
1–8 to yield Ang 1–7 and Ang 1–5 when compared to the en-
zyme-free controlsample(Figure 3(a)).AlthoughtheplasmaInternational Journal of Hypertension 5
Table 1: Enzymatic properties of rhACE2 and rmACE2. The sub-
strate turnover rates and product formation rates were determined
for the kinetic experiments in Figure 2. Therefore, the slope of
the linear regressions across all data points was determined for
both substrate-product pairs and both enzymes. The mean of the
absolute values for the substrate degradation rates and product
formation rates for each enzyme were related to the molar concen-
trationofrhACE2orrmACE2.Theresulting valuesforkcat aregiven
in the table.
kcat [s−1]
rhACE2 rmACE2
Ang 1–8 ≥ Ang 1–7 7.7 × 10
−1 6.2 ×10
−1
Ang 1–10 ≥ Ang 1–9 1.8 × 10
−2 1.3 ×10
−3
concentration of Ang 1–10 was only 161pg/mL (124pM), a
concentration of 5μg/mL (58,8nM) rhACE2 was found to
eﬃciently convert Ang 1–10 to Ang 1–9, as indicated by the
peptide levels depicted in the RAS-Fingerprints (Figure 3(a),
right). In contrast to rhACE2, rmACE2 was unable to de-
crease Ang 1–10 concentrations in plasma and failed to
induce detectable Ang 1–9 levels (Figure 3(a), middle). Of
note, the increase of Ang 1–7 and Ang 1–5 in the presence
of rhACE2 was even more prominent, due to this second
pathway of Ang 1–7 production via Ang 1–9, which was
selectively supported only by rhACE2.
As in vitro experiments revealed that rmACE2 was capa-
ble of converting Ang 1–10 to Ang 1–9, although to a much
lower extent compared to rhACE2, we further investigated
the capability of rmACE2 for Ang 1–9 formation in human
plasma at increased Ang 1–10 concentrations. We added
the ACE-inhibitor Lisinopril to our ex vivo setting, in order
to prevent ACE-mediated degradation of ACE2-produced
Ang 1–9 and to increase Ang 1–10 levels by preventing
its degradation by endogenous ACE. The presence of
Lisinopril led to signiﬁcantly increased Ang 1–10 peptide
levels compared to untreated control samples (710pg/mL
versus 161pg/mL) (Figures 3(a) and 3(b) left). Comparison
of rhACE2 and rmACE2 activities in Lisinopril-treated
complete human plasma revealed that rhACE2 eﬀectively
converts large amounts of Ang 1–10 to Ang 1–9 in the
physiological matrix while rmACE2 was found to be much
less eﬀective in catalysing this reaction (Figure 3(b)).
Interestingly, Lisinopril was not able to increase Ang 1–
7 concentrations in our experimental settings, which was in
contrast to several published reports. No Ang 1–7 was de-
tectable in plasma samples incubated with Lisinopril in the
absence or presence of rhACE2 or rmACE2 (Figure 3(b))
meaning thatthe concentrationwas below the quantiﬁcation
limit of 2pg/mL plasma. For further investigation of these
surprising results, the experiment was repeated for rhACE2
in whole blood instead of plasma. Whole blood incubations
gave similar results as previously reported by other groups,
showing an increase of Ang 1–7 concentrations in con-
trol and rhACE2 samples in response to Lisinopril (see Sup-
plementary Figure 1 available online at doi:10.1155/2012/
428950).
For further investigation of rmACE2 and rhACE2 sub-
strate speciﬁcities, diﬀerent states of RAS activity were sim-
ulated by addition of lower amounts of recombinant human
renin in the presence of Lisinopril, conﬁrming our ﬁndings
about strongly diverging conversion rates for Ang 1–10
between rhACE2 and rmACE2 in a substrate concentration-
dependent manner (Figure 3(c)). These results demonstrate
th a tA n g1–10s erv esa san a tura ls ubs tra t ef orr h A CE2w h ic h
is eﬃciently processed under physiological conditions. In
c o n t r a s tt ot h a t ,r m A C E 2i sm u c hl e s se ﬀective regarding this
catalytic conversion, strongly supporting a species-speciﬁc
roleofACE2intheactivationofthealternativeRASpathway.
4.Discussion
We expressed and puriﬁed both rhACE2 and rmACE2 in
CHO cells under serum-free conditions. Both cell lines were
stably secreting high levels of recombinant proteins for at
least two months of roller bottle cultivation. The quality
of the expression products did not change from early to
the latest passages. Both rhACE2 and rmACE2 appeared as
stable homo-dimers, while we did not identify monomeric
or other multimeric forms. We evaluated the quality of the
enzyme preparations by multiple methods including HPLC,
SEC, SDS-PAGE, and native PAGE which all conﬁrmed the
purity of the ﬁnal products and their homo-dimeric tertiary
structure (Figure 1). Despite the similarity of the calcu-
lated molecular weights for human and murine monomers,
surprisingly high mass diﬀerences between rhACE2 and
rmACE2wereobservedinSECandcouldbeﬁnallyidentiﬁed
to be caused by species-speciﬁc sequence variations which
lead to a diﬀerent number in N-glycosylation sites in human
and murine ACE2.
ACE2 is known to cleave a variety of peptide substrates
in vitro [18], which are involved in a broad panel of physio-
logical functions [17]. Based on our ﬁndings about the dif-
ferences in tertiary structure between rhACE2 and rmACE2,
we hypothesized that the well-known sequence diversity
between the two species might have an impact on the func-
tional characteristics of the enzymes. Therefore, we assessed
the turnover rates for rhACE2 and rmACE2 for two natural
and physiologically important substrates (Ang 1–10 and Ang
1–8) in a well-deﬁned in vitro model system (Figure 2). We
selected these substrates for ACE2 characterization because
of their functional importance in maintaining RAS peptide
levels. It has been described previously that the angiotensin
peptides Ang 1–8 and Ang 1–10 are cleaved by ACE2 in vitro
[6]. As the conversion rates of ACE2 for Ang 1–10 were
reported to be substantially slower than those for Ang 1–
8, this enzyme reaction was supposed to take over a minor
role in the formation of Ang 1–7 than the direct production
by Ang 1–8 cleavage. We could conﬁrm previous ﬁndings
regarding substrate preferences and found a 42-fold higher
turnover number for Ang 1–8 compared to Ang 1–10 when
cleaved by rhACE2 (Table 1). Interestingly, our values for
kcat were lower compared to previous publications which
might have been caused by diﬀerences in the employed ex-
perimental settings, in particular because of diﬀerent buﬀer6 International Journal of Hypertension
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Figure 3: Interference of human and murine ACE2 with the endogenous RAS in human plasma. Anticoagulated plasma samples were
incubated at 37◦C in the presence of 100pg/mL recombinant human renin (a, b). rhACE2 or rmACE2 were added as indicated at a ﬁnal
plasma concentration of 5μg/mL. RAS-Fingerprints were measured by LC-MS/MS as indicated in Section 2.S a m p l e sw e r ei n c u b a t e di nt h e
absence (a) or presence (b) of 10μM of the ACE inhibitor Lisinopril. In this ﬁgure, the diameter of the spheres reﬂects the concentration
of the respective peptide metabolite, which is also given in pg/mL next to each individual sphere. 0pg/mL indicates concentrations below
quantiﬁcation limits, which are deﬁned by a signal-to-noise ratio below 10. Furthermore, the amino acid sequence of each angiotensin
metabolite is schematically given in brackets beside the corresponding sphere. The sequence annotation is based on the decapeptide
Angiotensin I (1–10) which is N- or C-terminally cleaved by the indicated proteases. Proteases are illustrated by arrows connecting their
substrate and product. AP: aminopeptidases; NEP: neutral endopeptidase; DAP: di-aminopeptidase; ACE: angiotensin-converting enzyme.
(c) Indicated concentrations of recombinant human renin were added to Lisinopril-treated plasma samples. Control samples (black bars),
rmACE2- (grey bars), and rhACE2- (white bars) treated samples were subjected to RAS-Fingerprinting, and resulting concentrations for
Ang 1–10 (left) and Ang 1–9 (right) are given in pg/mL.International Journal of Hypertension 7
systems. Nevertheless, the qualitative conclusions were com-
parable and internally controlled. While showing compara-
bleturnoverratesforAng1–8,theAng1–10-relatedturnover
rate for rmACE2 was found to be only 7% of the respective
rateforrhACE2.Thisfundamentaldiﬀerenceinthesubstrate
conversionratesofthetwoenzymesmightalso havesubstan-
tial impact on the regulation of the RAS under physiologic
conditions in the two diﬀerent species.
Unfortunately,onlylimitedconclusionsaboutphysiolog-
ical consequences can be drawn out of in vitro experiments.
An important feature of the physiologic conditions in blood
plasma is that all RAS enzymes except renin are present in
excess compared to their substrates, which is the exact oppo-
site of the in vitro situation. Although in vitro investigations
a r ev e r yu s e f u lf o rt h ec o m p a r i s o no fe n z y m ec h a r a c t e r i s t i c s
in one and the same model system, they tell us very little
about the in vivo situation.
Therefore, we developed an ex vivo experimental setup
which allowed us to investigate the enzymatic function of
thetwo recombinant enzymesin theirphysiological environ-
ment, with their natural substrates being present at picomo-
lar concentrations. We would like to point out that these ex
vivo conditions reﬂect the human in vivo plasma conditions
regarding circulating enzyme concentrations after systemic
administration of rhACE2 (data not shown). Although ex
vivo incubations are very reproducible and reﬂect an inte-
grated picture of soluble enzyme activities throughout the
RASinundilutedplasma, theangiotensinpeptideconcentra-
t i o n sa r ec l e a r l yh i g h e ri nex vivo incubated plasma samples,
which might be caused by a lack of the peptide ﬂow towards
organs or endothelial surfaces ex vivo.
We investigated the RAS in these samples by means of
a newly developed LC-MS/MS method, which allows the
quantiﬁcation of multiple angiotensin metabolites simulta-
neously in one single sample of blood plasma. The obtained
RAS-Fingerprints revealed that, in contrast to rmACE2,
rhACE2 is capable to generate Ang 1–9 from Ang 1–10 at
physiologic peptide concentrations (Figure 3). This activity
even more gains importance in the presence of the ACE-
inhibitor Lisinopril, which blocks the formation of Ang 1–
8. Under latter conditions, large amounts of Ang 1–9 are
generated in the plasma samples by rhACE2, while rmACE2
is much less eﬀective in its formation of Ang 1–9 from Ang
1–10.
Although signiﬁcant amounts of Ang 1–10 and Ang 1–9
were present in samples treated with Lisinopril alone or in
combination with rhACE2, no Ang 1–7 could be detected in
these samples. These ﬁndings were in contrast to previously
published reports on Ang 1–7 accumulating eﬀects of ACE
inhibitors in vivo [20, 21]. In our experimental setting, we
employed heparinized blood plasma as a sample matrix for
ACE2 characterization which is reﬂecting in vivo conditions
very well. However, plasma lacks all blood cells which might
carry receptors and angiotensin peptide converting enzymes
being able to aﬀect angiotensin peptide concentrations in
vivo. Comparison of plasma and whole blood samples
revealed that Lisinopril-induced Ang 1–7 accumulation is
strictly dependent on blood cell-associated angiotensin pep-
tide converting enzymes, as it was exclusively observed in
whole blood ex vivo incubations (Figure 3(b), Supplemen-
tary Figure 1). As neutral endopeptidase (NEP, CD10) is
known to be expressed on the cell surface of leukocytes
[22,23]andthatitisabletoconvertAng1–10andAng1–9to
Ang 1–7 in vitro [18], NEP is very likely to be responsible for
Ang 1–7 accumulation also in vivo, especially in the presence
of ACE inhibitors which blockt h ef o r m a t i o no fA n g1 – 8
which is an important precursor for Ang 1–7.
In human plasma, the ACE2-mediated formation of Ang
1–9 from Ang 1–10 represents a signiﬁcant route of estab-
lishment of the alternative RAS. This may be, for example,
of particular importance in vivo, when ACE inhibitors are
used for antihypertensive treatment. As ACE2 is primarily
expressed as a membrane-attached enzyme in several organs
[24], the local production of Ang 1–9 from Ang 1–10 which
is increased when ACE inhibitors are present, might become
an important mechanism of action for ACE inhibitors action
in vivo in humans. In addition to Ang 1–7, also Ang 1–9 has
been reported to possess protective eﬀects in cardiovascular
disease models [25]. These mechanistic considerations seem
to be of particular importance in humans, while murine
model systems for the investigation of ACE inhibitor eﬃcacy
might be reconsidered in respect to the species-speciﬁc lack
of Ang 1–10 cleavage by murine ACE2.
Altogether, our ﬁndings describe important species-
speciﬁc diﬀerences in the ﬁne speciﬁcity of ACE2. Thus, the
murine RAS is likely to function diﬀerently when compared
toitshumancounterpart.Furthermore,ourdatapointtothe
importance of further investigations and improved under-
standing of the human RAS, while data generated in murine
model systems might be partially reconsidered in respect
to diﬀerent enzyme properties. Deciphering the functional
characteristics of the human RAS using new analytical possi-
bilitiesrevealspreviously invisible featuresofthesystem. The
future generation of human-derived data describing RAS
function in health and disease will pave the way for new
concepts of therapeutic manipulations of the system which
are more speciﬁcally designed for application in humans.
References
[1] J. Stegbauer and T. M. Coﬀman, “New insights into angiot-
ensin receptor actions: from blood pressure to aging,” Current
OpinioninNephrologyandHypertension,vol.20,no.1,pp.84–
88, 2011.
[2] Y .C.Zhu,Y .Z.Zhu,N.L u,M.J .W ang,Y .X.W ang,andT .Y ao ,
“Role of angiotensin AT1 and AT2 receptors in cardiac hyper-
trophy and cardiac remodelling,” Clinical and Experimental
Pharmacology and Physiology, vol. 30, no. 12, pp. 911–918,
2003.
[3] L. Zhou, R. Zhang,W. Yao et al., “Decreased expression of an-
giotensin-converting enzyme 2 in pancreatic ductal adenocar-
cinoma is associated with tumor progression,” Tohoku Journal
of Experimental Medicine, vol. 217, no. 2, pp. 123–131, 2009.
[4] Z. J. Cheng, H. Vapaatalo, and E. Mervaala, “Angiotensin II
and vascular inﬂammation,” Medical Science Monitor, vol. 11,
no. 6, pp. RA194–RA205, 2005.
[5] W.R. HuckleandH. SheltonEarp, “Regulation ofcell prolifer-
ation and growth by angiotensinII,” Progress in Growth Factor
Research, vol. 5, no. 2, pp. 177–194, 1994.8 International Journal of Hypertension
[6] S. R. Tipnis, N. M. Hooper, R. Hyde, E. Karran, G. Christie,
and A. J. Turner, “A human homolog of angiotensin-convert-
ing enzyme: cloning and functional expression as a captopril-
insensitive carboxypeptidase,” J o u r n a lo fB i o l o g i c a lC h e m i s t r y ,
vol. 275, no. 43, pp. 33238–33243, 2000.
[ 7 ] C .M .F e r r a r i o ,M .C .C h a p p e l l ,E .A .T a l l a n t ,K .B .B r o s n i h a n ,
and D. I. Diz, “Counterregulatory actions of angiotensin-(1-
7),” Hypertension, vol. 30, no. 3, pp. 535–541, 1997.
[ 8 ]R .A .S .S a n t o s ,A .C .S i m o e seS i l v a ,C .M a r i ce ta l . ,“ A n g i o t -
ensin-(1-7)isanendogenousligandfortheGprotein-coupled
receptor Mas,” Proceedings of the National Academy of Sciences
of the UnitedStates of America, vol.100,no.14,pp.8258–8263,
2003.
[9] J. Zhong, R. Basu, D. Guo et al., “Angiotensin-converting
enzyme 2 suppresses pathological hypertrophy, myocardial
ﬁbrosis, and cardiac dysfunction,” Circulation, vol. 122, no. 7,
pp. 717–728, 2010.
[10] M. Donoghue, F. Hsieh, E. Baronas et al., “A novel angiotens-
in-converting enzyme-related carboxypeptidase (ACE2) con-
verts angiotensin I to angiotensin 1-9,” Circulation Research,
vol. 87, no. 5, pp. E1–E9, 2000.
[11] Y. Imai, K. Kuba, and J. M. Penninger, “The discovery of angi-
otensin-converting enzyme 2 and its role in acute lung injury
in mice,” Experimental Physiology, vol. 93, no. 5, pp. 543–548,
2008.
[12] M. A. Crackower, R. Sarao, G. Y. Oudit et al., “Angiotensin-
converting enzyme 2 is an essential regulator of heart func-
tion,” Nature, vol. 417, no. 6891, pp. 822–828, 2002.
[13] G. Y. Oudit, Y. Imai, K. Kuba, J. W. Scholey, and J. M. Pen-
ninger, “The role of ACE2 in pulmonary diseases—relevance
forthenephrologist,”Nephrology DialysisTransplantation,v o l .
24, no. 5, pp. 1362–1365, 2009.
[14] B. Treml, N. Neu, A. Kleinsasser et al., “Recombinant angi-
otensin-converting enzyme 2 improves pulmonary blood ﬂow
and oxygenation in lipopolysaccharide-induced lung injury in
piglets,” Critical Care Medicine, vol. 38, no. 2, pp. 596–601,
2010.
[15] C.H. ¨ Osterreicher,K.Taura,S.DeMinicisetal.,“Angiotensin-
converting-enzyme 2 inhibits liver ﬁbrosis in mice,” Hepatol-
ogy, vol. 50, no. 3, pp. 929–938, 2009.
[ 1 6 ]F .L o v r e n ,Y .P a n ,A .Q u a ne ta l . ,“ A n g i o t e n s i nc o n v e r t -
ing enzyme-2 confers endothelial protection and attenuates
atherosclerosis,” American Journal of Physiology, vol. 295, no.
4, pp. H1377–H1384, 2008.
[17] C. Vickers,P. Hales,V. Kaushik et al., “Hydrolysis of biological
peptides by human angiotensin-converting enzyme-related
carboxypeptidase,” J o u r n a lo fB i o l o g i c a lC h e m i s t r y , vol. 277,
no. 17, pp. 14838–14843, 2002.
[ 1 8 ]G .I .R i c e ,D .A .T h o m a s ,P .J .G r a n t ,A .J .T u r n e r ,a n dN .
M. Hooper, “Evaluation of angiotensin-converting enzyme
(ACE), its homologue ACE2 and neprilysin in angiotensin
peptide metabolism,” Biochemical Journal, vol. 383, no. 1, pp.
45–51, 2004.
[19] T. Komatsu, Y. Suzuki, J. Imai et al., “Molecular cloning,
mRNA expression and chromosomal localization of mouse
angiotensin-converting enzyme-related carboxypeptidase
(mACE2),” DNA Sequence, vol. 13, no. 4, pp. 217–220, 2002.
[20] C. M. Ferrario, J. Jessup, P. E. Gallagher et al., “Eﬀects of
renin-angiotensinsystem blockade onrenalangiotensin-(1-7)
formingenzymesandreceptors,” Kidney International, vol.68,
no. 5, pp. 2189–2196, 2005.
[21] S. N. Iyer, M. C. Chappell, D. B. Averill, D. I. Diz, and
C. M. Ferrario, “Vasodepressor actions of angiotensin-(1-7)
unmasked during combined treatment with lisinopril and
losartan,” Hypertension, vol. 31, no. 2, pp. 699–705, 1998.
[ 2 2 ]B .M a r i ,J .P .B r e i t t m a y e r ,S .G u e r i ne ta l . ,“ H i g hl e v e l so f
functional endopeptidase 24.11 (CD10) activity on human
thymocytes: preferential expression on immature subsets,”
Immunology, vol. 82, no. 3, pp. 433–438, 1994.
[23] R. Tran-Paterson, G. Boileau, V. Giguere, and M. Letarte,
“Comparative levels of CALLA/neutral endopeptidase on
normal granulocytes, leukemic cells, and transfected COS-1
cells,” Blood, vol. 76, no. 4, pp. 775–782, 1990.
[ 2 4 ]Z .W .L a i ,I .H a n c h a p o l a ,D .L .S t e e r ,a n dA .I .S m i t h ,“ A n g i -
otensin-converting enzyme 2 ectodomain shedding cleavage-
site identiﬁcation: determinants and constraints,” Biochem-
istry, vol. 50, no. 23, pp. 5182–5194, 2011.
[25] M. P. Ocaranza,S. Lavandero,J.E. Jalilet al.,“Angiotensin-(1-
9) regulates cardiac hypertrophy in vivo and in vitro,” Journal
of Hypertension, vol. 28, no. 5, pp. 1054–1064, 2010.